期刊文献+

吡格列酮联合二甲双胍对2型糖尿病患者胰岛素抵抗及炎性因子的影响 被引量:13

Effect of pioglitazone and metformin on insulin resistance and inflammatory factors in type 2 diabetic patients
下载PDF
导出
摘要 目的观察吡格列酮及二甲双胍联合治疗2型糖尿病对患者胰岛素抵抗指数与炎性因子水平的影响。方法94例2型糖尿病患者随机分为观察组和对照组,分别给予吡格列酮联合二甲双胍、二甲双胍治疗12周,观察治疗前后胰岛素抵抗指数和炎性因子水平,评价治疗效果。结果观察组疗效优于对照组(Hc=6.513,P<0.05),治疗后两组患者胰岛素抵抗指数明显降低,且观察组指标降低更为显著(P<0.01),观察组治疗后超敏C反应蛋白、IL-6水平显著降低,且均低于对照组(P<0.01)。结论吡格列酮及二甲双胍联合治疗2型糖尿病可改善胰岛素抵抗、降低炎性因子水平。 Objective To observe the effect of pioglitazone and metformin on insulin resistance(IR) index and inflammatory factor level in patients with type 2 diabetes mellitus(T2DM). Methods Ninety-four patients with T2DM were randomly treated with pioglitazone plus metformin(observation group) or metformin(control group) for 12 weeks. IR index,inflammatory factor level, and clinical efficacy were compared between two groups before and after treatment. Results Clinical efficacy was better in observation group than in control group(Hc=6.5131, P〈0.05). IR index was lowered in both groups after treatment, especially in observation group(P〈0.01), while hypersensitive C-reactive protein and IL-6 level was decreased only in observation group(P〈0.01). Conclusion Combined use of pioglitazone and metformin can improve IR and reduce inflammatory factor level in patients with T2DM.
作者 陈镇涛 王苓 CHEN Zhen-tao;WANG Ling(Zhangmutou Hospital of Dongguan City,Dongguan 523622,China)
出处 《广东医科大学学报》 2018年第2期138-140,共3页 Journal of Guangdong Medical University
关键词 吡格列酮 二甲双胍 2型糖尿病 胰岛素抵抗 pioglitazone metformin type 2 diabetes mellitus insulin resistance
  • 相关文献

参考文献9

二级参考文献99

  • 1李焱,程桦.2型糖尿病、动脉粥样硬化与炎症[J].中华内分泌代谢杂志,2005,21(6). 被引量:11
  • 2谭庆华,韦晓勇,潘海涛,胡小玲,麦少玲.二甲双胍、吡格列酮联合应用治疗肥胖2型糖尿病患者的疗效观察[J].医学文选,2006,25(4):586-588. 被引量:7
  • 3颜红梅,高鑫,刘蒙,顾迁,张斌,李湘,高键,赵耐青.非酒精性脂肪肝与代谢综合征关系的研究[J].中国糖尿病杂志,2006,14(5):326-328. 被引量:74
  • 4任婷婷,郭晓蕙,徐国恒.二甲双胍改善脂质代谢及胰岛素敏感性的机制[J].临床药物治疗杂志,2007,5(4):11-13. 被引量:9
  • 5Bloomgarden ZT. Inflammation and insulin resistance[J]. Diabetes Care,2003,26(5) ..1619-1620.
  • 6Kanter JE, Averill MM, Leboeuf RC, et al. Diabetes-accel- erated atherosclerosis and inflammation [J]. Circ Res, 2008,103(8) :116-117.
  • 7Pickup JC,Cruok MA. Is type ]] diabetes mellitus a dis- ease of the innate immune system[J]. Diabetologia, 1998, 41(10) .. 1241-1248.
  • 8Abdulkadir AA, Thanoon IA. Comparative Effects of Glibenclamide and Metformin on C-reactive Protein and Oxidant/Antioxidant Status in Patients with Type II Di- abetes Mellitus[J]. Sultan Qaboos Univ Med J, 2012,12 (1) :55-61.
  • 9Einhorn D, Rendell M, Rosenzweig J, et al. Pioglitazonehydrochloride in combination with metformin in the treatmentof type 2 diabetes mellitus: a randomized, placebo-controlledstudy. The Pioglitazone 027 Study Group [J]. Clin Ther, 2000,22(2): 1395-1409.
  • 10Perez A, Zhao Z, Jacks R, et al. Efficacy and safety ofpioglitazone/metformin fixed-dose combination therapycompared with pioglitazone and metformin monotherapy intreating patients with T2DM[J]. Curr Med Res Opin, 2009,25(12): 2915-2923.

共引文献155

同被引文献127

引证文献13

二级引证文献45

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部